Alectinib for the treatment of papillary thyroid carcinoma harbouring STRN - ALK fusion.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
first line alectinib for the treatment of a STRN - ALK translocated advanced thyroid carcinoma with symptomatic bilateral lung localizations
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
The dose of alectinib was progressively reduced due to the toxicity, but the treatment is still ongoing after 17 months with complete radiological response and clinical benefit. [CONCLUSION] Here we report the first case in Europe of STRN - ALK translocated advanced thyroid carcinoma successfully treated with alectinib.
[BACKGROUND] Anaplastic Lymphoma Kinase (ALK) rearrangement is a rare alteration in differentiated thyroid carcinomas (DTCs).
APA
Buriolla S, Zapelloni G, et al. (2025). Alectinib for the treatment of papillary thyroid carcinoma harbouring STRN - ALK fusion.. European journal of cancer (Oxford, England : 1990), 216, 115193. https://doi.org/10.1016/j.ejca.2024.115193
MLA
Buriolla S, et al.. "Alectinib for the treatment of papillary thyroid carcinoma harbouring STRN - ALK fusion.." European journal of cancer (Oxford, England : 1990), vol. 216, 2025, pp. 115193.
PMID
39721296 ↗
Abstract 한글 요약
[BACKGROUND] Anaplastic Lymphoma Kinase (ALK) rearrangement is a rare alteration in differentiated thyroid carcinomas (DTCs). Due to its low prevalence, a few evidence are available about the use of ALK inhibitors in advanced DTCs.
[METHODS] We report the case of a striatin (STRN) - ALK translocated advanced thyroid carcinoma. STRN - ALK translocation was detected by NGS - RNA analysis.
[RESULTS] A 74-year-old woman received first line alectinib for the treatment of a STRN - ALK translocated advanced thyroid carcinoma with symptomatic bilateral lung localizations. The dose of alectinib was progressively reduced due to the toxicity, but the treatment is still ongoing after 17 months with complete radiological response and clinical benefit.
[CONCLUSION] Here we report the first case in Europe of STRN - ALK translocated advanced thyroid carcinoma successfully treated with alectinib.
[METHODS] We report the case of a striatin (STRN) - ALK translocated advanced thyroid carcinoma. STRN - ALK translocation was detected by NGS - RNA analysis.
[RESULTS] A 74-year-old woman received first line alectinib for the treatment of a STRN - ALK translocated advanced thyroid carcinoma with symptomatic bilateral lung localizations. The dose of alectinib was progressively reduced due to the toxicity, but the treatment is still ongoing after 17 months with complete radiological response and clinical benefit.
[CONCLUSION] Here we report the first case in Europe of STRN - ALK translocated advanced thyroid carcinoma successfully treated with alectinib.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Carbazoles
- Female
- Aged
- Piperidines
- Anaplastic Lymphoma Kinase
- Thyroid Neoplasms
- Thyroid Cancer
- Papillary
- Protein Kinase Inhibitors
- Oncogene Proteins
- Fusion
- Treatment Outcome
- Translocation
- Genetic
- Calmodulin-Binding Proteins
- Membrane Proteins
- Nerve Tissue Proteins
- ALK fusion
- Advanced thyroid cancer
- Agnostic therapy
- Target therapy
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.